Figure 5
Impact of del(17p13) on PFS and OS. For all patients with del(17p13), the median PFS times (A) and 3-year OS rates (B) in the bortezomib-based treatment arm B were better compared with the standard arm A.
Impact of del(17p13) on PFS and OS. For all patients with del(17p13), the median PFS times (A) and 3-year OS rates (B) in the bortezomib-based treatment arm B were better compared with the standard arm A.
